M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways (International Journal of Cancer (2007) 121, (2317-2330))
Michele Caraglia,Manuela Marra,Caterina Viscomi,Anna Maria D'Alessandro,Alfredo Budillon,Giuseppina Meo,Claudio Arra,Antonio Barbieri,Ulf R. Rapp,Alfonso Baldi,Pierfrancesco Tassone,Salvatore Venuta,Alberto Abbruzzese,Pierosandro Tagliaferri +13 more
Journal ArticleDOI
Peptide Functionalization of Silicon for Detection and Classification of Prostatic Cells
Jane Politi,Silvia Zappavigna,Ilaria Rea,Paolo Grieco,A. Caliò,Amalia Luce,Michele Caraglia,Luca De Stefano +7 more
TL;DR: In this paper, a silicon-based biochip for prostate cancer PC3 cells detection by using cytokeratin 8/18 and Urotensin Receptor (UTR) as markers in order to obtain a biochip-based diagnostic system.
Journal ArticleDOI
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
V. Caputo,Vincenzo De Falco,Anna Ventriglia,Vincenzo Famiglietti,Erika Martinelli,Floriana Morgillo,Giulia Martini,Carminia Maria Della Corte,Davide Ciardiello,L. Poliero,Ferdinando De Vita,Michele Orditura,Morena Fasano,Renato Franco,Michele Caraglia,Arianna Avitabile,R. Scalamogna,Beatrice Marchi,Fortunato Ciardiello,Teresa Troiani,Stefania Napolitano +20 more
TL;DR: Although additional studies are needed to better select patients and setting, NGS F1LA is a useful, noninvasive, and repeatable assay to guide therapeutic choice in oncology.
Journal ArticleDOI
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment.
Francesco Pantano,Francesco Maria Guida,Caterina Vivaldi,Bruno Vincenzi,Enrique Grande,Mercedes Rodriguez Garrote,Michele Caraglia,Nicola Silvestris,Enrico Vasile,Gianluca Masi,Alfredo Falcone,Giuseppe Tonini,Daniele Santini +12 more
TL;DR: The aim of this study was to evaluate the feasibility to stratify patients more likely to benefit from Cetuximab treatment using two well-known signs of hyperinsulinemic state such as the high Body Mass Index (BMI) and impaired Fasting Blood Glucose (FBG).
Journal ArticleDOI
Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
Pierpaolo Correale,Antonio Procopio,Luigi Celio,Michele Caraglia,Geppino Genua,Vincenzo Coppola,Stefano Pepe,Nicola Normanno,Immacolata Vecchio,Giovannella Palmieri,S Montagnani,Pierosandro Tagliaferri,Angelo Raffaele Bianco +12 more
TL;DR: Evaluating the effects of PMA on the expression at the cell surface of adhesion factors and extracellular matrix proteins found that the acquisition of a NK- and LAK-resistant phenotype by GLL-19 cells occurs together with cell differentiation, down-regulation of membrane expression of collagen IV, ICAM-1 and vitronectin receptor, but in the absence of changes in MHC antigens.